Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra.
about
Dopamine Receptors and NeurodegenerationA Role for the Brain RAS in Alzheimer's and Parkinson's DiseasesAnnular protofibrils are a structurally and functionally distinct type of amyloid oligomer.L-type calcium channel blockers and Parkinson disease in Denmark.Nox4-generated superoxide drives angiotensin II-induced neural stem cell proliferation.Brain Renin-Angiotensin System and Microglial Polarization: Implications for Aging and Neurodegeneration.Angiotensin II type 1/adenosine A 2A receptor oligomers: a novel target for tardive dyskinesia.Antihypertensive agents and risk of Parkinson's disease: a nationwide cohort studyBrain renin-angiotensin system and dopaminergic cell vulnerabilityDiscovery of inhibitors of insulin-regulated aminopeptidase as cognitive enhancers.Loss of angiotensin II receptor expression in dopamine neurons in Parkinson's disease correlates with pathological progression and is accompanied by increases in Nox4- and 8-OH guanosine-related nucleic acid oxidation and caspase-3 activationGeneration of reactive oxygen species in 1-methyl-4-phenylpyridinium (MPP+) treated dopaminergic neurons occurs as an NADPH oxidase-dependent two-wave cascade.Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease.Angiotensin II AT(1) receptor blockers ameliorate inflammatory stress: a beneficial effect for the treatment of brain disorders.Frataxin Deficiency Promotes Excess Microglial DNA Damage and Inflammation that Is Rescued by PJ34Angiotensin II, a Neuropeptide at the Frontier between Endocrinology and Neuroscience: Is There a Link between the Angiotensin II Type 2 Receptor and Alzheimer's Disease?Activation of MyD88-dependent TLR1/2 signaling by misfolded α-synuclein, a protein linked to neurodegenerative disorders.Mitochondrial angiotensin receptors in dopaminergic neurons. Role in cell protection and aging-related vulnerability to neurodegeneration.Expression of angiotensinogen and receptors for angiotensin and prorenin in the rat and monkey striatal neurons and glial cells.Importance of the brain Angiotensin system in Parkinson's diseaseThe Angiotensin II Type 2 Receptor in Brain Functions: An Update.Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's diseaseA High Affinity Red Fluorescence and Colorimetric Probe for Amyloid β Aggregates.Peganum Harmala L. Extract Reduces Oxidative Stress and Improves Symptoms in 6-Hydroxydopamine-Induced Parkinson's Disease in RatsMolecular mechanisms and clinical implications of reversible protein S-glutathionylation.Crosstalk between insulin-like growth factor-1 and angiotensin-II in dopaminergic neurons and glial cells: role in neuroinflammation and aging.The angiotensin converting enzyme inhibitor captopril protects nigrostriatal dopamine neurons in animal models of parkinsonismPrevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors.The role of the central renin-angiotensin system in Parkinson's disease.The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases.How does angiotensin AT(2) receptor activation help neuronal differentiation and improve neuronal pathological situations?Dopamine-angiotensin interactions in the basal ganglia and their relevance for Parkinson's disease.Rho Kinase and Dopaminergic Degeneration: A Promising Therapeutic Target for Parkinson's Disease.Reciprocal regulation between sirtuin-1 and angiotensin-II in the substantia nigra: implications for aging and neurodegeneration.Interaction between NADPH-oxidase and Rho-kinase in angiotensin II-induced microglial activation.Microglial TNF-α mediates enhancement of dopaminergic degeneration by brain angiotensin.Role of Tissue Renin-angiotensin System and the Chymase/angiotensin-(1-12) axis in the Pathogenesis of Diabetic Retinopathy.Angiotensin II protects against alpha-synuclein toxicity and reduces protein aggregation in vitro.The MPTP Story.The intracellular angiotensin system buffers deleterious effects of the extracellular paracrine system.
P2860
Q26783348-E3C46E5B-01BA-4E90-A299-8762F4C12851Q26861984-E5CC49BD-C65A-4743-B2A0-634291FC0941Q30157440-31552DDE-FF26-47C8-879D-8FAF67CCF4AFQ30495902-3C3C7781-C8AB-400A-916D-70BC9C31AE9FQ30564117-0503F6F6-CB95-4B5A-BF82-3ACABEE2FEDCQ33627982-645E8FCA-9684-4723-99B4-9C44C7F16387Q33687719-2D7A6144-BBA0-4C72-A4E6-48A080151D63Q33727268-1A73B60D-08C5-414A-AC65-6EF8BA903DA4Q33861951-9BF414D1-431A-4B3B-88F7-2B539C3083EBQ34543485-3FC50DB6-3E85-4308-B348-9B1683B3F9BFQ35177092-176B16CE-AF8F-46F1-AC25-ADEE3C132CDCQ35416073-160F4B39-D541-4D72-B3ED-1BC16265BFAEQ35819219-01EC9B6B-8407-47C6-9143-4B8816103217Q35827935-4F74D3B0-4A73-4594-85C8-B176BEDCF5DFQ35949121-5D58EA4B-AF43-43C0-930D-8595D87FEDF8Q35971305-9733B83A-C2E7-4036-8E54-20AC4B419BE3Q36148314-9D1F33C7-F22E-4FF4-AE67-EC458F152D9FQ36168905-09518E07-5799-4EDF-896C-C7CF6F48401DQ36270869-1ED7768B-B47E-45D8-9CEB-33FA339D3D76Q36415423-9577DE2A-35D1-4737-88DB-2DD0F05229B2Q36520049-5A436F1A-C103-4BB1-AC18-F7111E4D8E6BQ36576487-ED5C19C7-2EBF-4164-9B1F-BB519F41ABC2Q36754686-CAEE6FA7-2AD8-4176-8C24-72768F6FB44EQ37178127-A6EE4A97-EE14-47DF-A08A-932C2BBD64E3Q37262124-739AB352-1CCE-493A-948C-1F26F1FE2A28Q37327417-79112001-090A-4108-A473-D2F42AD9BAEAQ37467929-3EA48CA5-8F89-4B8A-AFB8-427C3D149A30Q37600876-55D423B5-10FE-4DBE-95BD-E250D6E28038Q37622568-34C0713F-5798-4E5B-8AED-FE62866540FDQ38005611-7A118C58-F14F-4842-9902-E3A1D1CC75DFQ38069825-963081B2-4674-4283-BD93-6DEA85893D13Q38127396-DC70203A-CA8B-4903-BA60-7023176C87A8Q38260925-2C0DE356-05AD-434B-9F22-882B74D0C0A0Q38834345-7F653797-515E-476F-BFC9-DF5E8F412023Q38942116-6778E4E5-1EC0-4F46-A4EC-2F6EF8C19751Q39055955-780DE9EF-DE28-4570-B670-12AFBF8E042DQ39238324-FAC945E7-3464-477B-A15A-6F94FBF4BFF4Q40075301-AAFD0A8F-89CA-4250-8EDC-967C321B1CC3Q41825283-4639921B-F2AF-41DA-80F2-E723488DEECFQ42261440-B4BBC514-C786-4513-B836-9C70D3245D81
P2860
Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Angiotensin type 1 receptor an ...... c neurons in substantia nigra.
@ast
Angiotensin type 1 receptor an ...... c neurons in substantia nigra.
@en
type
label
Angiotensin type 1 receptor an ...... c neurons in substantia nigra.
@ast
Angiotensin type 1 receptor an ...... c neurons in substantia nigra.
@en
prefLabel
Angiotensin type 1 receptor an ...... c neurons in substantia nigra.
@ast
Angiotensin type 1 receptor an ...... c neurons in substantia nigra.
@en
P2093
P2860
P50
P356
P1476
Angiotensin type 1 receptor an ...... ic neurons in substantia nigra
@en
P2093
Andy M Poczobutt
Brian R Hoover
Ferogh A Ahmadi
James A Weyhenmeyer
Lawrence D Snell
Vimal V Jhaveri
W Michael Zawada
P2860
P2888
P356
10.1186/1750-1326-2-1
P577
2007-01-15T00:00:00Z
P5875
P6179
1031823757